Drug Profile
TK 001
Alternative Names: TK-001Latest Information Update: 11 Sep 2023
Price :
$50
*
At a glance
- Originator Takis
- Class Cancer vaccines
- Mechanism of Action Immunostimulants; Oncogene protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Breast cancer; Head and neck cancer; Ovarian cancer
Most Recent Events
- 11 Sep 2023 TK 001 is still in preclinical development for Ovarian cancer, Breast cancer and Head and neck cancer in Italy
- 28 Aug 2020 No recent reports of development identified for preclinical development in Breast-cancer in Italy
- 28 Aug 2020 No recent reports of development identified for preclinical development in Head-and-neck-cancer in Italy